A three-arm randomized trial to compare adjuvant adriamycin [doxorubicin] and cyclophosphamide followed by taxotere (AC-T) [docetaxel]; adriamycin and taxotere (AT); adriamycin, taxotere and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 18 Jan 2013 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2011 Results of a prespecified subanalysis published in the Journal of Clinical Oncology.